Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
NCT06430684
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are: Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)? Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Kidney Diseases
- Pediatric Kidney Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 12 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Last updated on ClinicalTrials.gov
- August 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.